Verona Pharma plc (VRNA)
| Market Cap | 3.18B |
| Revenue (ttm) | 5.62M |
| Net Income (ttm) | -153.72M |
| Shares Out | 81.83M |
| EPS (ttm) | -1.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,155,655 |
| Open | 38.00 |
| Previous Close | 38.09 |
| Day's Range | 37.61 - 39.33 |
| 52-Week Range | 11.39 - 40.13 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 43.83 (+12.82%) |
| Earnings Date | Nov 4, 2024 |
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing en... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for VRNA stock is "Strong Buy." The 12-month stock price forecast is $43.83, which is an increase of 12.82% from the latest price.
News
Verona Pharma Announces December 2024 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
Verona Pharma to Present at Jefferies London Healthcare Conference
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarte...
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune r...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effe...
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.
Top 3 Health Care Stocks That May Crash In August
As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial O...
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.
Top 3 Health Care Stocks You May Want To Dump This Quarter
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quart...
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from S...
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
US FDA approves Verona Pharma's therapy for 'smoker's lungs'
The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects ...
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these...
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Verona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval. Potential competition from ...
Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer...
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:...